MiNK Therapeutics(INKT) - 2024 Q1 - Earnings Call Transcript

We do believe that mechanistically that the combination of BOT/BAL iNKT with standard of care may not only be beneficial to patients but also quite tolerable and we've been able to demonstrate that so far in the first patient to have been enrolled. We do have patients that have been exposed to all five agents and those patients are tolerating the combinations quite well and we're pretty excited to share an update on those, which we expect will be the second half of this year. Given the pace of enrollment in ...